ABSTRACT: Intracellular protein transduction technology is opening the door for a promising alternative to gene therapy. Techniques have to address all critical steps, like efficient cell uptake, endolysosomal escape, low toxicity, while maintaining full functional activity of the delivered protein.
■ INTRODUCTION
Today many different proteins, including recombinant growth factors and monoclonal antibodies, are used in cancer therapy and modern medicine. 1, 2 However, up to date application in therapy is largely limited to proteins whose site of action is extracellular at the surface of target cells. Cytosolic delivery of proteins, due their size and charge, for a long time has been conceived as impractical. The first observed protein that was naturally able to translocate through the intact phospholipid bilayer was the HIV-1 TAT protein. 3, 4 In the meantime, it has been discovered that natural homeoproteins such as the Antennapedia homeobox can cross cell membranes and internalize into cells as part of their physiological function, 5 and numerous homeoprotein-derived natural and artificial transduction peptides have been identified. 6−9 Thus, the intracellular delivery of active proteins, named protein transduction, now is considered as an interesting option and alternative to gene therapy, substituting for dysfunctional cellular proteins. 10−12 Protein transduction is expected to be a safe approach, lacking the introduction of potentially recombinogenic nucleic acid material. 13 In addition, the technology offers the possibility to transport chemically modified proteins, containing, for example, artificial or Damino acids, considered to be less immunogenic and more stable toward proteolytic degradation. On the bench side, intracellular protein delivery technology offers innumerable possibilities, like localization, interaction, and many other studies. For in vitro studies, it is possible to use physical methods, like microinjection or electroporation, to promote an uptake of the desired protein. 14, 15 Alternatively, such as for therapeutic application, a transfection carrier molecule is needed. The transfection carrier has to prevent the cargo from extracellular degradation and has to transport it across the biological barrier of the cell membrane. Once inside the cell, the carrier−cargo complex has to avoid endolysosomal degradation either by direct transfer into the cytosol or by escape from endolysosomal vesicles after endocytosis. Afterward, the carrier should release its cargo in the cytosol or be sufficiently inert to warrant full functional activity of the protein. A perfect carrier system should combine all these entry functions with low cytotoxicity. In the last decades, many efforts have been made to create such a perfect carrier system. Aside from rather exotic technologies, for example, virus-like particles, 16 carbon nanotubes, 17, 18 and mesoporous silica, 19, 20 the most common techniques are protein delivery with cationic lipids, 21, 22 protein transduction domains (PTDs), 11,23−25 and cationic polymers. 26−31 Each of these technologies has got its limitations such as cell type dependence 32 or borders certain cargo proteins. 33 Most commercially available protein trans-fection shuttles are based on cationic lipids. A major drawback of this technology is low stability under serum conditions. 34 Protein delivery with cell penetrating peptides, which can be grouped in two major classes, natural ones like penetratin 25, 35 or HIV-TAT 11 and artificial ones such as oligoarginines, 32 is the best investigated strategy. Protein transduction domains (PTDs) or cell penetrating peptides (CPPs) as they are also commonly called are tagged to the cargo protein by genetic engineering. Especially in cases where the active center of an enzyme is located near the carboxy-or amino-terminus, this tag may disturb functionality. The internalization pathway of these fusion proteins is controversial. Some studies suggest macropinocytosis, 36, 37 others predict that it is a mixture between different mechanisms. 38−40 The efficiency of the following step, the retrograde transport out of the endosome is low for most PTDs 41, 42 and dependent on cell line and cargo size. 32, 39 Cationic transfection polymers like polyethylenimine often are very effective but are lacking of precise structure and often show high toxicity dependent on the molecular weight of the used polymer. [27] [28] [29] [30] 43 In this study, we investigate the properties of the three-arm cationic oligomer 386 as a shuttle for intracellular protein delivery. This carrier molecule, in contrast to other cationic polymers used for intracellular delivery, is of precise structure and low molecular weight. In contrast to structure defined carriers, purification, analytics, reproducibility, and a clear structure−activity relationship are problematic steps when using polymers of distributed molecular weight. Oligomer 386 was recently designed for siRNA delivery. 44, 45 Protein delivery places different demands on a carrier than nucleic acid delivery. While the use as a nucleic acid carrier was based on electrostatic complex formation, this is not generally feasible for proteins, which exhibit much lower charge densities, varying from protein to protein. The transfection oligomer 386 was covalently bound to cargo proteins (β-galactosidase or enhanced green fluorescent protein) by a bioreversible disulfide bond. Covalent coupling of the carrier 386 was indispensable for forming an effective transduction shuttle. Such disulfide conjugations have been previously shown to be reversible upon cytosolic delivery. 46, 47 Our results reveal that covalent disulfide coupling of the defined cationic oligomer 386 to a protein leads to a highly efficient (even in presence of serum) and low toxic alternative to established protein transfection technologies.
■ EXPERIMENTAL SECTION
General. All chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), unless noted otherwise. SPDP (Nsuccinimidyl 3-(2-pyridyldithio) propionate) was synthesized as described elsewhere. 48 β-Galactosidase from E. coli (EC: 232-864-1) was purchased from Sigma-Aldrich (Taufkirchen, Germany). Neuro2A neuroblastoma cells (ACC-148) and the murine fibroblast cell line NIH-3T3 (ACC 59) were purchased from DSMZ (Braunschweig, Germany).
Cloning, Heterologous Expression, and Purification of nlsEGFP and HIV-TAT-nlsEGFP. nlsEGFP was prepared analogously as described previously. 49 HIV-TAT-nlsEGFP was prepared by annealing and cloning the following oligonucleotides encoding for HIV-TAT sequence into the heterologous expression of the nlsEGFP designed vector. 49 Sense: 5′AGCTTGGTTATGGGCGCAAAAAACGCCGTCAGC-GCCGTCGGGGCC3′. Antisense: 5′TCGAGGCCCCGA-CGGCGCTGACGGCGTTTTTTGCGCCCATAACCA 3′.
By the common calcium chloride method, this plasmid was transformed into E. coli BL21(DE3)plysS (Novagen, Merck4-biosciences, Darmstadt, Germany). Under constant shaking in TB medium (37°C), the cells were grown to an optical density of 0.75 (600 nm). Protein expression was induced with isopropyl β-D-1-thiogalactopyranoside (Biomol, Hamburg, Germany) (final concentration 1 mM), and expression was continued for another 16 h. After ultrasonic cell lysis, the nlsEGFP was purified by nickel chromatography using a gradient from binding buffer (50 mM sodium hydrogen phosphate, 300 mM sodium chloride, and 20 mM imidazole) to elution buffer (50 mM sodium hydrogen phosphate, 500 mM sodium chloride, and 250 mM imidazole). The protein was dialyzed overnight at 4°C against PBS buffer (pH 7.3) using a dialysis membrane (MWCO 14,000 Da) from Carl Roth (Karlsruhe, Germany). Finally, the TAT-nlsEGFP was concentrated with an Amicon Ultra centrifugal filter units (MWCO 10,000 Da).
Modification of Cargo Proteins with an SPDP Linker Molecule. Modification of β-Galactosidase. β-Galactosidase (3 mg, 0.026 μmol) was diluted in PBS buffer (1 mL; pH 7.3, 1 mM EDTA). Then, SPDP (succinimidyl 3-(2-pyridyldithio)-propionate) was dissolved in DMSO (50 μL; 0.775 μmol) and added to the above protein solution (30-fold molar excess compared to β-galactosidase). After incubation (2 h; 20°C), the unconjugated linker was removed by size exclusion chromatography (Sephadex G25 superfine) using PBS buffer (pH 7.3, 1 mM EDTA) as the mobile phase. The modified protein was concentrated with Amicon Ultra centrifugal filter units (MWCO 10,000; Millipore (Billerica, MA)). The protein concentration was determined at 280 nm using a molar extinction coefficient of 210000
. The ratio of linker to protein could be calculated, after reducing a sample of the modified protein with DTT (dithiothreitol) and determination of the change in absorbance (343 nm; 8080 M −1 cm
−1
). Modification of nlsEGFP. nlsEGFP (3 mg, 0.095 μmol) was diluted in PBS buffer (1 mL; pH 7.3, 1 mM EDTA). Then SPDP (succinimidyl 3-(2-pyridyldithio)propionate) was dissolved in DMSO (50 μL; 1.14 μmol) and added to the above protein solution. After incubation (2 h; 20°C), the unconjugated linker was removed by size exclusion chromatography (Sephadex G25 superfine) using PBS buffer (pH 7.3, 1 mM EDTA) as the mobile phase. The modified protein was concentrated with Amicon Ultra centrifugal filter units (MWCO 10,000 Da; Millipore (Billerica, MA)). Protein concentration was quantified by measurement of the absorbance at a wavelength of 488 nm using an extinction coefficient of 55000 M −1 cm −1 . The ratio of linker to protein could be calculated, after reducing a sample of the modified protein with DTT (dithiothreitol) and determination of the change in absorbance (343 nm; 8080 M −1 cm
). Conjugation of Proteins with Transfection Oligomer 386. Transfection oligomer 386 was synthesized as previously reported. 44 SPDP modified proteins (1 mg) were diluted in Hepps buffer (1 mL, 0.5 M, pH 8.5) and 2-fold molar excess of oligomer 386 (compared to covalently bound linker), which was predissolved in water (50 mg/mL), was added for the modification of nlsEGFP. For the modification of β-galactosidase, a 5-fold molar excess of oligomer 386 (compared to covalently bound linker), which was predissolved in water (50 mg/mL), was used. Thereafter, the pH was adjusted to 7.5 with aqueous HCl (1 M) in both cases. The product was purified, after 1 h of incubation (20°C) by Amicon Ultra centrifugal filter units (MWCO 10,000 Da; 3× washing steps with PBS buffer and 1 mM EDTA, pH 7.3).
Cell Culture. 3T3 murine fibroblasts cells were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with FCS (10%), glucose (4g/l), stable glutamine (4 mM), sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (100 μg/mL). Neuro2A were cultured in DMEM (1.0g/L glucose) supplemented with FCS (10%), and 100 U/mL penicillin and streptomycin (100 μg/mL). All cells were cultured in a 37°C incubator with 5% CO 2 supply and humidified atmosphere.
Cell Viability Assay. The metabolic activity of transfected cells was determined by the MTT assay. Neuro2A or 3T3 cells were seeded in 96-well tissue culture plates (TPP, Transdingen, Switzerland) at a density of 15000 cells per well, the day before transfection. Cells were transfected with different concentrations of 386-SS-nlsEGFP (0.1; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5 μM) in 100 μL of growth media (containing 10% FCS) for 2 h. After washing with PBS and incubating in fresh media (24 h), MTT solution (10 μL per well, 5.0 mg/mL MTT in phosphate-buffered saline, pH 7.4) was added. The medium was replaced by 100 μL of DMSO after 3 h. The optical absorbance was measured at 590 nm, with a reference wavelength of 630 nm, by a microplate reader (Spectraflour Plus, Tecan Austria GmbH, Austria). The metabolic activity of the transduced cells was expressed as relative cell viability, compared to untreated cells.
β-Galactosidase Transfection. Neuro2A cells were seeded in 6 well plates (250000 cells per well; one day before transfection) and transfected with 1 or 2.5 μM 386-β-galactosidase (in cell culture media containing 10% FCS) for 2 h. For X-Gal staining, a method which was previously described was used. 50 After transfection, cells were washed with PBS (containing 500 IU heparin per mL and subsequently fixed with (1.25% (v/v) glutaraldehyde). Following two additional washing steps with PBS, X-gal staining solution (50 mMTris/ HCl; pH 7.5; 5 mM potassium ferrocyanate, 5 mM potassium ferricyanate,15 mM sodium chloride, 1 mM magnesium chloride, 0.1% Triton, and 0.5 mg/mL X-gal) was added and incubated for 3 h (37°C). Afterward, the cells were washed once more with PBS and analyzed with a phase contrast microscope. For quantitative flow cytometric analysis, C12-FDG (Invitrogen, Karlsruhe, Germany) substrate was used. Neuro2A cells (250000) were seeded in 6 well plates the day before transfection. Transfection was done by pipetting 386-SS-β-galactosidase into the growth media. After 2 h of incubation, the cells were washed two times with PBS buffer supplemented with 500 IU heparin per mL. Afterward, the cells were covered with fresh growth media containing 2.0 μM C12-FDG. After incubation for 45 min, the cells were washed again with PBS and evaluated by flow cytometry.
nlsEGFP Transfection Experiments. For fluorescence microscopy, 24 h prior to transfection 20000 cells were seeded in 8 well Nunc chamber slides (Thermo Scientific, Braunschweig, Germany). Before transfection, the medium was replaced with fresh medium. Subsequently, the oligomer modified nlsEGFP was pipetted (final concentration 1 μM) into cell culture media (10% FCS). After 2 h of incubation, the cells were washed with PBS buffer (pH 7.3) containing 500 IU heparin per mL. Afterward, fresh medium was added, and 2 h later, the cells were examined under the microscope. For FACS experiments, 24 h prior to transfection 250000 cells were seeded in 6-well plates. Before transfection, the medium was replaced with fresh medium containing 10% FCS. Subsequently, the oligomer modified nlsEGFP was pipetted into the cell culture media (usually 0.5 μM, except for the uptake vs concentration experiment 0.25; 0.5; 0.75; 1.0; 1.5 μM). After incubation (usually 120 min, except for the uptake vs time experiment 15; 30; 60; 120; 180 min), cells were washed two times with PBS buffer (pH 7.3; 500 IU heparin per mL).
Flow Cytometry. 3T3 or Neuro2A cells were seeded in 6-well plates (250000 cells/well). After transfection and washing as described above, cells were detached with trypsin/EDTA, diluted with growth media containing 10% FCS, harvested by centrifugation, and taken up in phosphate-buffered saline with 10% FCS. Flow cytometry was performed using a Cyan ADP flow cytometer (Dako, Hamburg, Germany). The cellular fluorescence was assayed by excitation of nlsEGFP or C12-FDG at 488 nm and detection of emission at 510 nm. To discriminate between viable and dead cells as well as for exclusion of doublets, cells were appropriately gated by forward/sideward scatter and pulse width, and counterstained with propidium iodide. Ten thousand gated cells per sample were collected. Data was recorded with SummitT software (Summit, Jamesville, NY). Evaluation was done using FlowJo software (Treestar, Ashland, Oregon, USA).
Endocytosis Inhibition. This experiment was performed as described elsewhere, 31 with minor modifications. Briefly, 250000 cells were seeded in 6 well plates. Before transfection, the medium was replaced with fresh medium containing 1 mM amiloride (inhibitor for macropinocytosis), 5 μg/mL chloropromazine (inhibitor for clathrin-mediated endocytosis), or 2.5 mM β-cyclodextrin (inhibitor for caveolae-mediated endocytosis). After 30 min of incubation, the oligomer modified nlsEGFP was pipetted into the cell culture media (0.5 μM). After 120 min, cells were washed two times with PBS buffer (pH 7.3, 500 IU heparin per mL) and subsequently analyzed by flow cytometry.
Particle Size and Zeta Potential. Particle size and zeta potential of the transfection shuttles were measured by dynamic laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Modified proteins were measured in Hepes buffer (20 mM, pH 7.4) at a concentration of 5 mg/mL. In investigations of the effect of serum on particle size and zeta potential, 10% FCS was added.
Fluorescence Microscopy and Phase Contrast Microscopy. For fluorescence microscopy observation, the nuclei of the cells were stained by pipetting Hoechst Dye 33342 (1 μg/ mL) into the cell culture media. Ten minutes later, the cells were observed on an Axiovert 200 fluorescence microscope from Zeiss (Jena, Germany). A 40× phase 1 objective or a 63× magnification DIC oil immersion objective (Plan-APOCHRO-MAT) and appropriate filter sets for analysis of EGFP and Hoechst fluorescence were used. Data were analyzed and processed by AxioVision LE software (Zeiss, Jena, Germany). For phase contrast microscopy, also an Axiovert 200 microscope from Zeiss (Jena, Germany) was used. Pictures were taken using a 10× magnification phase 1 contrast objective.
Activity Test of Modified β-Galactosidase. The formation of a fluorescent product (4-methylumbelliferone (4-MU); λ excitation 360 nm, λ emission 440 nm) out from the nonfluorescent 4-methylumbelliferone-β-D-galactopyranosidesubstrate (MUG) by hydrolysis through β-galactosidase 51 was used to determine the relative activity of modified β-galactosidase, compared to that of the unmodified enzyme. The assay was performed with minor modification as described elsewhere. 52 Briefly, the MUG (1 mM, nonlimiting surplus) substrate was dissolved in PBS buffer (pH 7.4; 5 mM MgCl 2 ). The reaction was started by the addition of enzyme (0.5 μg/ mL). Enzyme kinetics was monitored by following the formation of the fluorescent 4-MU product over time on a Varian Cary Eclipse fluorescence spectrophotometer. As the substrate was used in nonlimiting surplus, the enzyme activity is displayed by the slope of the curve.
■ RESULTS AND DISCUSSION
For evaluating intracellular delivery of proteins, we have chosen two model cargos: β-galactosidase, a big 464-kDa homotetramer, where enzymatic activity can be checked histochemically and by flow cytometry; and a tagged EGFP protein, which has average protein size (32 kDa) and can be followed in cellular uptake by flow cytometric methods and in intracellular distribution by fluorescence microscopy. A nuclear localization signal (SV40 large T-antigen) tagged EGFP (nlsEGFP) was selected because only free cytosolic nlsEGFP (and not endosomal captured nlsEGFP) can translocate into the nucleus; thus, this feature was utilized to indicate endosomal escape and natural subcellular behavior. 53 An overview of the transfection concept with disulfide linked 386 is illustrated in Scheme 1.
The covalent attachment of the carrier 386 to the cargo proteins (β-galactosidase, nlsEGFP) is schematically displayed in Scheme 2. The biological reversible covalent chemical conjugation between synthetic molecules or peptides and proteins via SPDP linker is a well-established method. 54 At an average, 5 linker molecules were introduced per EGFP molecule. Each β-galactosidase molecule was modified with an average of 8 linker molecules.
These linker molecules bearing activated thiol groups were used for the biological reversible covalent attachment of the cationic transfection oligomer 386.
The formed disulfide bonds should be cleavable by glutathione in the cytosol after endosomal release, resulting in a carrier free nlsEGFP or β-galactosidase. 46, 55 The successful modification and reversibility of the disulfide bonds are documented in Supporting Information, Figure S1 .
Dynamic light scattering revealed for 386-conjugates nlsEGFP particle sizes of 26.8 ± 3.6 nm and a zeta potential of 12.4 ± 0.6 mV. The presence of 10% serum decreased zeta potential to 5.32 ± 0.1 mV and lead to the formation of heterogeneous particles with sizes between 32 and 360 nm. For 386-modified β-galactosidase, we obtained particles of 48.3 ± 2.4 nm with a surface charge of 9.5 ± 0.2 mV. In the presence of 10% FCS, the particle sizes for 386-SS-β-Gal ranged between 51 and 460 nm, and the zeta potential decreased to 4.49 ± 0.5 mV. To investigate the ability of these transfection shuttles to penetrate cells and promote endosomal release and natural subcellular transport, cells were transfected as described in the Experimental Section. Uptake and subcellular distribution of nlsEGFP conjugates were pursued using a fluorescence microscope. Figure 1 Figure 3A ). All standard transfections were performed in the presence of 10% fetal bovine serum. To evaluate the influence of serum, a comparison of transfections with (white bars) or without (gray bars) serum was made (Figure 3 B) . A considerable influence of serum on transfection efficiency was observed only at transfection concentrations at 0.5 μM or lower.
We had expected that the amount of internalized material is concentration dependent, as was already reported for CPPassisted transfection studies. 40 Nevertheless, we were quite surprised about the nearly perfect linear relationship between concentration of protein transfection conjugate and fluorescence intensity for both cell types in the tested concentration area. Similar linear dependency of concentration and uptake was already reported for internalization mediated by the protein transduction domain Antp (Antennapedia-homeodomain). 38 In the following experiment, we performed a time-course (Figure 4) . Uptake of 386-SS-nlsEGFP increased with incubation time, resulting in the observed increased fluorescence intensity (Figure 4 ). After 15 min of incubation time around 45% and after 30 min incubation already over 90% of the cells were EGFP positive when transfection was performed with 0.5 μM 386-SSnlsEGFP. Such a continuous uptake is supposed to be a strong hint for endocytosis-mediated uptake. 38 Transfection at 4°C dramatically lowers internalization of the modified protein ( Figure 5 ) in 3T3 cells. Cells transfected at 4°C exhibited only 25% of the fluorescence compared to that of control cells transfected at 37°C. This observation indicates that internalization of 386-modified nlsEGFP is an energy-dependent process and is consistent with most CPPs. 31, 40, 56 To further analyze the endocytotic pathway in 3T3 cells, we did transfection experiments in the presence of chlorpromazine (inhibits clathrin-mediated endocytosis), amiloride (inhibits macropinocytosis), and β-cyclodextrin (inhibits caveolaemediated endocytosis). All these endocytosis inhibitors reduced transfection efficiency at least a little bit, suggesting that all three endocytosis pathways participate in internalization. Clathrin-mediated endocytosis is the predominant internalization route, as chlorpromazine reduced fluorescence to 55% compared to control cells, transfected under standard conditions. Caveolae-mediated endocytosis and macropinocytosis seem to contribute, respectively, to around 15−20% of the uptake. The finding that clathrin-mediated endocytosis may be the major internalization route is in accordance with the measured particle size, as particles smaller than 200 nm are supposed to be taken up mainly through this pathway. 57 Aoyama and co-workers found that receptor-mediated endocytosis is strongly size-dependent with an optimum of around 25 nm. 58−60 This correlates exactly with the measured size of the transfection shuttles and the observed uptake pathway.
Flow cytometry experiments using 0.5 μM 386-SS-nlsEGFP further demonstrate that internalized nlsEGFP disappears after a few days ( Figure 6 ). This finding was expected as due to cell proliferation, the intracellular nlsEGFP concentration is dying out. Another reason might be proteosomal degradation. Twenty-four hours after transfection, the cells lost approximately one-third of their original mean fluorescence. Within 48 h after transfection, the fluorescence decreased to a fourth and after 72 h to below 10% of the primordial value.
In addition to transfection of the fluorescent protein nlsEGFP, transfection of the enzyme β-galactosidase, a big 464 kDa homotetramer, was evaluated. Disulfide conjugation to 386 resulted in considerably reduced enzyme activity ( Figure  7A) . A possible reason for this finding may be the disturbance of the tertiary structure of the enzyme due to the charge inversion of the protein, as unmodified β-Gal is a protein with a negative isoelectric point (theoretical pI 5.8), and the formation of rather large protein conjugate particles (48 nm, see above). Nevertheless, Neuro2A cells transduced with 386-SS-β-Gal are able to hydrolyze the X-Gal (5-bromo-4-chloro-3-indoxyl-β-Dgalactopyranoside) substrate into β-galactose and the colored hydroxyindole product 61 ( Figure 7B ). Only cells that were transduced with 386-SS-β-Gal (but not with unmodified β-Gal) were stained blue. For a more quantitative analysis, we used C12-FDG as the substrate, which led to FITC fluorescence after enzymatic cleavage. Fluorescence was quantified by flow cytometry, revealing fluorescence of the 386-SS-β-Gal transduced cells but not of cells transduced with unmodified β-Gal ( Figure 7C ). Data show that transfection oligomer 386 is able to transport remarkable amounts of active β-Gal enzyme into cells, even at the low transfection concentration of 1 μM.
Oligomer 386 was shown to exhibit low cytotoxicity when used as a carrier for siRNA or pDNA. 44 To verify the nontoxic properties also in case of protein delivery, a cell viability test was performed. This confirmed this assumption. Figure 8 shows the low cytotoxicity of the transfection shuttle even at high concentrations. It exhibited only marginally higher effects on cell growth and metabolism than unmodified nlsEGFP protein or TAT-nlsEGFP. With the standard concentration used for the transfections above (0.5 μM), a decline in metabolic activity of only 11% in comparison to that of growing untreated cells was observed (24 h after transfection). Even after transfection with 2.5 μM 386-SS-nlsEGFP, the metabolic cell activity decreased by only 29%.
■ CONCLUSIONS
We have shown that a sequence-defined cationic transfection oligomer, with low molecular weight, is applicable to protein delivery upon covalent disulfide conjugation and enables high efficient uptake in two different cell lines. Protein transfection efficiency is linear dependent on cargo−carrier conjugate concentration as well as on transfection time. Endocytosis was demonstrated as the main uptake pathway. The carrier coupling to the cargo protein through a biological reversible disulfide bond results in natural subcellular behavior after endosomal release, as demonstrated in nuclear delivery for the nls-tagged EGFP protein. The chemically precise transfection shuttle is based on natural and artificial amino acids providing a pH-responsive positive charge density (medium at extracellular pH, high at endosomal pH), resulting in efficient transfection (20 times more efficient than TAT peptide-mediated delivery). Furthermore, in contrast to polymeric carriers it has low molecular weight, exhibits no significant toxicity, and, when delivering an enzyme, was shown to maintain significant enzyme activity upon the transfection process. This technology is expected to be applicable to numerous other proteins. 
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